Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 2Hodgkin Disease 2Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 56fludarabine phosphate 30Filgrastim 28Peripheral Blood Stem Cell Transplantation 27Radiotherapy 26Cyclosporine 23Busulfan 23Etoposide 21Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 19Methotrexate 17Methylprednisolone 15Melphalan 14Cytarabine 13Vincristine 11Tacrolimus 11Thiotepa 10Prednisone 10Cord Blood Stem Cell Transplantation 10Rituximab 9Doxorubicin 9Leucovorin 7aldesleukin 6Granulocyte Colony-Stimulating Factor 6sargramostim 5Psychiatric Rehabilitation 5Carboplatin 5Therapeutics 4Daunorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Dendritic Cell Sarcoma, Interdigitating × iratumumab × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡